DK2710114T3 - Fremstilling med høj renhed af proteiner med multi-underenheder såsom antistoffer i transformerede mikrober såsom pichia pastoris - Google Patents

Fremstilling med høj renhed af proteiner med multi-underenheder såsom antistoffer i transformerede mikrober såsom pichia pastoris Download PDF

Info

Publication number
DK2710114T3
DK2710114T3 DK12789187.7T DK12789187T DK2710114T3 DK 2710114 T3 DK2710114 T3 DK 2710114T3 DK 12789187 T DK12789187 T DK 12789187T DK 2710114 T3 DK2710114 T3 DK 2710114T3
Authority
DK
Denmark
Prior art keywords
antibodies
proteins
units
high purity
pichia pastoris
Prior art date
Application number
DK12789187.7T
Other languages
Danish (da)
English (en)
Inventor
Patricia Dianne Mcneill
Nicole Janson
Gary L Lesnicki
Pei Qi
John A Latham
Leon F Garcia-Martinez
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK2710114T3 publication Critical patent/DK2710114T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK12789187.7T 2011-05-20 2012-05-08 Fremstilling med høj renhed af proteiner med multi-underenheder såsom antistoffer i transformerede mikrober såsom pichia pastoris DK2710114T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20
US201161496873P 2011-06-14 2011-06-14
US201161496860P 2011-06-14 2011-06-14
US201161525307P 2011-08-19 2011-08-19
PCT/US2012/036953 WO2012161956A2 (en) 2011-05-20 2012-05-08 High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris

Publications (1)

Publication Number Publication Date
DK2710114T3 true DK2710114T3 (da) 2021-12-06

Family

ID=47217961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12789187.7T DK2710114T3 (da) 2011-05-20 2012-05-08 Fremstilling med høj renhed af proteiner med multi-underenheder såsom antistoffer i transformerede mikrober såsom pichia pastoris

Country Status (22)

Country Link
EP (1) EP2710114B1 (enExample)
JP (2) JP6193220B2 (enExample)
KR (1) KR101981662B1 (enExample)
CN (2) CN110408644A (enExample)
CA (1) CA2837000C (enExample)
CY (1) CY1124796T1 (enExample)
DK (1) DK2710114T3 (enExample)
EA (1) EA028913B9 (enExample)
ES (1) ES2899381T3 (enExample)
HR (1) HRP20211873T1 (enExample)
HU (1) HUE060418T2 (enExample)
IL (1) IL229430B (enExample)
LT (1) LT2710114T (enExample)
MX (2) MX368546B (enExample)
PL (1) PL2710114T3 (enExample)
PT (1) PT2710114T (enExample)
RS (1) RS62628B1 (enExample)
SG (1) SG194937A1 (enExample)
SI (1) SI2710114T1 (enExample)
SM (1) SMT202100677T1 (enExample)
WO (1) WO2012161956A2 (enExample)
ZA (1) ZA201308639B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378344B (es) * 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
GB201803832D0 (en) * 2018-03-09 2018-04-25 Syndermix Ag Methods and compositions for lectin production
CN108913732B (zh) * 2018-07-31 2022-02-08 华东理工大学 一种莫纳可林j异源生产的方法及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6730499B1 (en) 1998-07-03 2004-05-04 Research Corporation Technologies, Inc. Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1
WO2000056903A2 (en) * 1999-03-22 2000-09-28 Zymogenetics, Inc. IMPROVED METHODS FOR PRODUCING PROTEINS IN TRANSFORMED $i(PICHIA)
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
PL204737B1 (pl) * 2000-12-13 2010-02-26 Unilever Nv Sposób wytwarzania heterologicznego białka przez grzyby
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
WO2008063302A2 (en) * 2006-10-10 2008-05-29 Keck Graduate Institute Novel p. pastoris pastoris promoters, and the use thereof to direct expression of proteins in yeast, preferably using a haploid mating strategy
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Also Published As

Publication number Publication date
MX368546B (es) 2019-10-07
CY1124796T1 (el) 2022-11-25
MX2013013532A (es) 2015-08-20
RS62628B1 (sr) 2021-12-31
IL229430A0 (en) 2014-01-30
ES2899381T3 (es) 2022-03-11
WO2012161956A9 (en) 2013-09-06
JP2018007656A (ja) 2018-01-18
IL229430B (en) 2020-07-30
WO2012161956A2 (en) 2012-11-29
HUE060418T2 (hu) 2023-02-28
JP6491696B2 (ja) 2019-03-27
EA028913B9 (ru) 2018-03-30
SMT202100677T1 (it) 2022-01-10
KR101981662B1 (ko) 2019-05-23
PT2710114T (pt) 2021-12-09
EA201301294A1 (ru) 2014-05-30
LT2710114T (lt) 2021-12-10
CN103827290A (zh) 2014-05-28
CN110408644A (zh) 2019-11-05
HRP20211873T1 (hr) 2022-03-04
MX2019012022A (es) 2019-11-18
EA028913B1 (ru) 2018-01-31
EP2710114B1 (en) 2021-11-03
EP2710114A2 (en) 2014-03-26
BR112013029902A2 (pt) 2016-12-20
CA2837000A1 (en) 2012-11-29
JP6193220B2 (ja) 2017-09-06
CA2837000C (en) 2021-09-14
PL2710114T3 (pl) 2022-01-17
NZ718187A (en) 2017-10-27
JP2014517698A (ja) 2014-07-24
KR20140033445A (ko) 2014-03-18
SI2710114T1 (sl) 2022-01-31
ZA201308639B (en) 2026-05-27
EP2710114A4 (en) 2014-11-19
SG194937A1 (en) 2013-12-30
WO2012161956A3 (en) 2013-01-17
NZ618635A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
DK2560683T4 (da) Fremstilling af heteromultimeriske proteiner
DK2771364T3 (da) Fremstilling af heterodimere proteiner
DK2896405T3 (da) Fremstilling af gadobutrol med høj renhed
DK3050972T3 (da) Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
DK3235907T3 (da) Metabolisk modificerede organismer til produktion af bioprodukter med merværdi
DK3336097T3 (da) Fremstilling af ikke-krystallinsk obeticholsyre
DK3029066T3 (da) Antistoffer med modificerede isoelektriske punkter
DK3321276T3 (da) Fusionsproteiner til behandling af metaboliske lidelser
HUE053745T2 (hu) Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2984942T3 (da) Modermælkserstatning med lavt proteinindhold med øget indhold af essentielle aminosyrer
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
DK2633007T3 (da) Produktion af regenererbar biobenzin
BRDI7105042S (pt) " configuração aplicada em jarra "
DK3235812T3 (da) Deutererede derivater af ivacaftor
DK2828208T3 (da) Aktivering af persulfater med organisk syre
DK2603219T3 (da) Kombination af GLYT1-forbindelse med antipsykotika
EP2723871A4 (en) IMPROVED PRODUCTION OF HETEROLOGICAL PROTEINS IN KLUYVEROMYCES MARXIANUS
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
DK2717712T3 (da) Fusion af bioaktive molekyler
IL230978B (en) A multi-copy strategy for high titer and high purity production of multi-subunit proteins such as antibodies in transformed bacteria such as P. pasteuris
DK2788014T3 (da) Anvendelse af væksthormonfragmenter
PT2739621T (pt) Cristais do composto 2-acilaminotiazol
DK2709833T3 (da) Støbning af fiberforstærket komposit
EP2771381A4 (en) Bacterial production of methyl ketones